Acorda Therapeutics Inc (ACOR) is a leading biotechnology business based in the US. It opened the day at $5.16 after a previous close of $5.19. During the day the price has varied from a low of $5.1046 to a high of $5.28. The latest price was $5.23 (25 minute delay). Acorda Therapeutics is listed on the NASDAQ and employs 167 staff. All prices are listed in US Dollars.
Best for
US shares
Best for
Index funds
Best for
Low-cost
Best for
Mobile trading
Since the stock market crash that started in February 2020, Acorda Therapeutics's share price has had significant negative movement.
Its last market close was $4.61, which is 49.45% down on its pre-crash value of $9.12 (accounting for the 3 January 2021 split) and 9.76% up on the lowest point reached during the March 2020 crash when the shares fell as low as $4.2 (accounting for the 3 January 2021 split).
If you had bought $1,000 worth of Acorda Therapeutics shares at the start of February 2020, those shares would have been worth $430.24 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $378.48.
| Open | $5.16 |
|---|---|
| High | $5.28 |
| Low | $5.1046 |
| Close | $5.23 |
| Previous close | $5.19 |
| Change | $0.04 |
| Change % | 0.7707% |
| Volume | 194,057 |
| 52-week range | $3.27 - $8.66 |
|---|---|
| 50-day moving average | $4.4635 |
| 200-day moving average | $4.2776 |
| Wall St. target price | $10 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-14.723 |
Other fees apply. Your capital is at risk.
Both exchange rates and share prices fluctuate in real time, so the costs presented here should be considered as a guide only. They do not incorporate stamp duty. Always refer to the platform itself for availability and pricing – which may differ from our information.
| Platform | Platform fee | Min. initial deposit | Trading fee estimate | |
|---|---|---|---|---|
|
£0 | No minimum | £1.70 £379.78 total |
Capital at risk |
|
£0 | $50 | £1.89 £379.97 total |
Capital at risk |
|
£0 | No minimum | £3.78 £381.86 total |
Capital at risk |
 |
£0 | £0.01 | £1.09 £379.17 total |
Capital at risk |
 |
£0 | £50 | £2.18 £380.26 total |
Capital at risk |
 |
£0 | £1 | £16.02 £394.10 total |
Capital at risk |
 |
£9.99 per month | No minimum | £13.95 £392.03 total |
Capital at risk |
 |
£36 per year | £20 | £14.52 £392.59 total |
Capital at risk |
Full comparison of share dealing platforms
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of $5.23
| 1 week (2021-10-13) | 12.96% |
|---|---|
| 1 month (2021-09-20) | 19.95% |
| 3 months (2021-07-20) | 39.47% |
| 6 months (2021-04-20) | 26.02% |
| 1 year (2020-10-20) | -9.39% |
|---|---|
| 2 years (2019-10-18) | -64.57% |
| 3 years (2018-10-19) | -95.12% |
| 5 years (2016-10-20) | -95.68% |
Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value.
Acorda Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A PEG ratio below 1 can be interpreted as meaning the shares are not overvalued given the current rate of growth.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
However, it's sensible to consider Acorda Therapeutics's PEG ratio in relation to those of similar companies.
| Revenue TTM | $151.9 million |
|---|---|
| Gross profit TTM | $96.8 million |
| Return on assets TTM | -8.1% |
| Return on equity TTM | -54.85% |
| Profit margin | -86.91% |
| Book value | $17.15 |
| Market capitalisation | $52.4 million |
TTM: trailing 12 months
There are currently 570,372 Acorda Therapeutics shares held short by investors – that's known as the "short interest". This figure is 24.7% down from 757,862 last month.
There are a few different ways that this level of interest in shorting Acorda Therapeutics shares can be evaluated.
Acorda Therapeutics's "short interest ratio" (SIR) is the quantity of Acorda Therapeutics shares currently shorted divided by the average quantity of Acorda Therapeutics shares traded daily (recently around 138104.60048426). Acorda Therapeutics's SIR currently stands at 4.13. In other words for every 100,000 Acorda Therapeutics shares traded daily on the market, roughly 4130 shares are currently held short.
To gain some more context, you can compare Acorda Therapeutics's short interest ratio against those of similar companies.
However Acorda Therapeutics's short interest can also be evaluated against the total number of Acorda Therapeutics shares, or, against the total number of tradable Acorda Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Acorda Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Acorda Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0612% of the tradable shares (for every 100,000 tradable Acorda Therapeutics shares, roughly 61 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Acorda Therapeutics.
Find out more about how you can short Acorda Therapeutics stock.
We're not expecting Acorda Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Acorda Therapeutics's shares were split on a 1:6 basis on 3 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acorda Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Acorda Therapeutics shares which in turn could have impacted Acorda Therapeutics's share price.
Over the last 12 months, Acorda Therapeutics's shares have ranged in value from as little as $3.27 up to $8.66. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics's is 0.5799. This would suggest that Acorda Therapeutics's shares are less volatile than average (for this exchange).
To put Acorda Therapeutics's beta into context you can compare it against those of similar companies.
Subscribe to trending stock alerts for a chance to win
Ever wondered how to buy shares in DatChat? We explain how and compare a range of providers that can give you access to many brands, including DatChat.
Ever wondered how to buy shares in Grove? We explain how and compare a range of providers that can give you access to many brands, including Grove.
Everything we know about the Cabify IPO, plus information on how to buy shares.
Everything we know about the SpaceX IPO, plus information on how to buy shares.
Everything we know about the Discord IPO, plus information on how to buy shares.
Everything we know about the Reddit IPO, plus information on how to buy shares.
Everything we know about the Li-Cycle IPO, plus information on how to buy shares.
Everything we know about the OrCam IPO, plus information on how to buy shares.
Everything we know about the Gopuff IPO, plus information on how to buy shares.
Everything we know about the Portillo’s IPO, plus information on how to buy shares.
